These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
995 related items for PubMed ID: 17594775
1. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M. Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775 [Abstract] [Full Text] [Related]
2. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G. Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192 [Abstract] [Full Text] [Related]
3. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884 [Abstract] [Full Text] [Related]
4. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators. J Bone Miner Res; 2005 Jan 30; 20(1):141-51. PubMed ID: 15619680 [Abstract] [Full Text] [Related]
5. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G. J Am Geriatr Soc; 2007 May 30; 55(5):752-7. PubMed ID: 17493196 [Abstract] [Full Text] [Related]
6. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group. J Bone Miner Res; 2004 Aug 30; 19(8):1259-69. PubMed ID: 15231012 [Abstract] [Full Text] [Related]
7. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME. Int J Clin Pract; 2008 Apr 30; 62(4):575-84. PubMed ID: 18324951 [Abstract] [Full Text] [Related]
8. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ. Aging (Milano); 2000 Feb 30; 12(1):1-12. PubMed ID: 10746426 [Abstract] [Full Text] [Related]
9. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R. J Bone Miner Metab; 2003 Feb 30; 21(6):421-7. PubMed ID: 14586800 [Abstract] [Full Text] [Related]
10. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. Bone; 2007 Jul 30; 41(1):122-8. PubMed ID: 17468062 [Abstract] [Full Text] [Related]
11. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R. Bone; 2006 Dec 30; 39(6):1268-75. PubMed ID: 16884968 [Abstract] [Full Text] [Related]
12. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME. J Intern Med; 2004 Apr 30; 255(4):503-11. PubMed ID: 15049885 [Abstract] [Full Text] [Related]
13. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal]. Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X. Zhonghua Yi Xue Za Zhi; 2002 Sep 25; 82(18):1254-6. PubMed ID: 12425805 [Abstract] [Full Text] [Related]
14. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Choi HJ, Im JA, Kim SH. Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334 [Abstract] [Full Text] [Related]
15. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L. Menopause; 2013 Jan 20; 20(1):72-8. PubMed ID: 22968256 [Abstract] [Full Text] [Related]
16. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group. J Clin Endocrinol Metab; 2001 Mar 20; 86(3):1116-25. PubMed ID: 11238495 [Abstract] [Full Text] [Related]
17. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Liu JH, Muse KN. Am J Obstet Gynecol; 2005 Apr 20; 192(4):1316-23; discussion 1323-4. PubMed ID: 15846228 [Abstract] [Full Text] [Related]
18. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. Iwamoto J, Takeda T, Sato Y, Uzawa M. J Bone Miner Metab; 2005 Apr 20; 23(3):238-42. PubMed ID: 15838627 [Abstract] [Full Text] [Related]
19. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH. J Bone Miner Res; 2005 Nov 20; 20(11):1905-11. PubMed ID: 16234962 [Abstract] [Full Text] [Related]
20. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH. Arch Dermatol; 2012 Mar 20; 148(3):307-14. PubMed ID: 22105813 [Abstract] [Full Text] [Related] Page: [Next] [New Search]